OncoTherapy Science, Inc. (TYO:4564)
Japan
· Delayed Price · Currency is JPY 27.00
+1.00 (3.70%)
Jul 3, 2025, 3:30 PM JST
OncoTherapy Science Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 750 | 610 | 1,134 | 1,153 | 332 | Upgrade
| |
Revenue Growth (YoY) | 22.95% | -46.21% | -1.65% | 247.29% | 5.06% | Upgrade
|
Cost of Revenue | 1,253 | 1,465 | 1,810 | 2,770 | 1,689 | Upgrade
|
Gross Profit | -503 | -855 | -676 | -1,617 | -1,357 | Upgrade
|
Selling, General & Admin | 289 | 261 | 287 | 294 | 281 | Upgrade
|
Other Operating Expenses | 5 | 4 | 144 | 142 | - | Upgrade
|
Operating Expenses | 294 | 265 | 431 | 436 | 281 | Upgrade
|
Operating Income | -797 | -1,120 | -1,107 | -2,053 | -1,638 | Upgrade
|
Interest Expense | -1 | - | - | - | - | Upgrade
|
Currency Exchange Gain (Loss) | 1 | -5 | -8 | -14 | -3 | Upgrade
|
Other Non Operating Income (Expenses) | -18 | -12 | -18 | -5 | 1 | Upgrade
|
EBT Excluding Unusual Items | -815 | -1,137 | -1,133 | -2,072 | -1,640 | Upgrade
|
Asset Writedown | - | -154 | -21 | -547 | -10 | Upgrade
|
Other Unusual Items | 2 | 5 | 38 | 49 | 90 | Upgrade
|
Pretax Income | -813 | -1,286 | -1,116 | -2,570 | -1,560 | Upgrade
|
Income Tax Expense | 2 | 2 | 2 | 1 | 1 | Upgrade
|
Earnings From Continuing Operations | -815 | -1,288 | -1,118 | -2,571 | -1,561 | Upgrade
|
Net Income | -815 | -1,288 | -1,118 | -2,571 | -1,561 | Upgrade
|
Net Income to Common | -815 | -1,288 | -1,118 | -2,571 | -1,561 | Upgrade
|
Shares Outstanding (Basic) | 261 | 213 | 193 | 187 | 176 | Upgrade
|
Shares Outstanding (Diluted) | 261 | 213 | 193 | 187 | 176 | Upgrade
|
Shares Change (YoY) | 22.73% | 10.45% | 2.76% | 6.31% | 8.14% | Upgrade
|
EPS (Basic) | -3.12 | -6.05 | -5.80 | -13.71 | -8.85 | Upgrade
|
EPS (Diluted) | -3.12 | -6.05 | -5.80 | -13.71 | -8.85 | Upgrade
|
Free Cash Flow | -815 | -1,229 | -798 | -2,529 | -1,805 | Upgrade
|
Free Cash Flow Per Share | -3.12 | -5.78 | -4.14 | -13.49 | -10.24 | Upgrade
|
Gross Margin | -67.07% | -140.16% | -59.61% | -140.24% | - | Upgrade
|
Operating Margin | -106.27% | -183.61% | -97.62% | -178.06% | -493.37% | Upgrade
|
Profit Margin | -108.67% | -211.15% | -98.59% | -222.98% | -470.18% | Upgrade
|
Free Cash Flow Margin | -108.67% | -201.47% | -70.37% | -219.34% | -543.67% | Upgrade
|
EBITDA | - | - | -1,091 | -2,037 | -1,589 | Upgrade
|
EBITDA Margin | - | - | -96.21% | -176.67% | - | Upgrade
|
D&A For EBITDA | - | - | 16 | 16 | 49 | Upgrade
|
EBIT | -797 | -1,120 | -1,107 | -2,053 | -1,638 | Upgrade
|
EBIT Margin | -106.27% | -183.61% | -97.62% | -178.06% | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.